The purpose of the study was to explore the association between metabolic syndrome (MetS) and chronic kidney disease (CKD) in perimenopausal women. A cross-sectional study was conducted in Zhuhai from June to October 2012. Perimenopausal women (n = 685) were included in the study. All participants were divided into three subgroups: Group 1, 40 years old ≤ Age < 50 years old; Group 2, 50 years old ≤ Age < 60 years old; Group 3, 60 years old ≤ Age ≤ 65 years old. MetS was associated with CKD ( p < 0.01) in the unadjusted analyses in total subjects. After adjusting the potential confounders, the odd ratios of CKD for MetS was 2.66 (95% CI 1.56 to 4.49, p < 0.001). There was no relationship between MetS and CKD in both Group 1 and Group 3. MetS was associated with CKD ( p < 0.001) in the unadjusted analyses in Group 2. After adjusting for potential confounders, MetS was significantly associated with CKD. The odd ratios for MetS was 6.79 (95% CI 2.30 to 20.09, p < 0.001). There was no relationship between elevated blood pressure, elevated fasting glucose, abdominal obesity, Low HDL cholesterol, elevated triglycerides and CKD in both Group 1 and Group 3. Elevated blood pressure was associated with CKD in Group 2 (unadjusted Odds ratio: 4.52 (1.28–16.02), p = 0.02). After adjusting for potential confounders, there was no relationship between elevated blood pressure and CKD ( p = 0.78). Elevated fasting glucose was associated with CKD in Group 2 (unadjusted Odds ratio: 3.69 (1.10–12.38), p = 0.03). After adjusting for potential confounders, there was no relationship between elevated fasting glucose and CKD ( p = 0.15). There was no relationship between abdominal obesity, Low HDL cholesterol, elevated triglycerides and CKD in Group 2. These findings suggest that in perimenopausal women aged from 50 or older to 60 MetS was associated with CKD. There is no relationship between MetS and CKD in perimenopausal women aged from 40 or older to 50 and aged from 60 or older to 65.
References
[1]
Nikolic, D.; Nikfar, S.; Salari, P.; Rizzo, M.; Ray, K.K.; Pencina, M.J.; Mikhailidis, D.P.; Toth, P.P.; Nicholls, S.J.; Rysz, J.; et al. Effects of statins on lipid profile in chronic kidney disease patients: A meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 2013, 29, 435–451, doi:10.1185/03007995.2013.779237.
[2]
Barylski, M.; Nikfar, S.; Mikhailidis, D.P.; Toth, P.P.; Salari, P.; Ray, K.K.; Pencina, M.J.; Rizzo, M.; Rysz, J.; Abdollahi, M.; et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol. Res. 2013, 72, 35–44, doi:10.1016/j.phrs.2013.03.007.
[3]
Athyros, V.G.; Hatzitolios, A.I.; Karagiannis, A.; Savopoulos, C.; Katsiki, N.; Tziomalos, K.; Papagianni, A.; Kakafika, A.; Gossios, T.D.; Mikhailidis, D.P.; et al. Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The imperative renal analysis. Arch. Med. Sci. 2011, 7, 984–992.
[4]
Barylski, M.; Ma？yszko, J.; Rysz, J.; My？liwiec, M.; Banach, M. Lipids, blood pressure, kidney—What was new in 2011? Arc. Med. Sci. 2011, 7, 1055–1066.
[5]
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39, S1–S266, doi:10.1016/S0272-6386(02)70081-4.
[6]
Zhang, L.; Wang, F.; Wang, L.; Wang, W.; Liu, B.; Liu, J.; Chen, M.; He, Q.; Liao, Y.; Yu, X.; et al. Prevalence of chronic kidney disease in China: A cross-sectional survey. Lancet 2012, 379, 815–822, doi:10.1016/S0140-6736(12)60033-6.
[7]
Coresh, J.; Selvin, E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298, 2038–2047, doi:10.1001/jama.298.17.2038.
[8]
Meguid, E.L.; Nahas, A.; Bello, A.K. Chronic kidney disease: The global challenge. Lancet 2005, 365, 331–340.
[9]
Muntner, P.; He, J.; Hamm, L.; Loria, C.; Whelton, P.K. Renal insuficiency and subsequent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol. 2002, 13, 745–753.
[10]
Malyszko, J.; Banach, M. Prediabetes, Prehypertension—Do We Need Pre-CKD? Curr. Vasc. Pharmacol. 25 April 2013. Available online: http://www.ncbi.nlm.nih.gov/pubmed/23627978 (accessed on 26 August 2013).
[11]
Curhan, G.C. Prediabetes, prehypertension—Is it time for pre-CKD? Clin. J. Am. Soc. Nephrol. 2010, 5, 557–559, doi:10.2215/CJN.01650210.
[12]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285, 2486–2497, doi:10.1001/jama.285.19.2486.
[13]
Tozawa, M.; Iseki, C.; Tokashiki, K.; Chinen, S.; Kohagura, K.; Kinjo, K.; Takishita, S.; Iseki, K. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007, 30, 937–943, doi:10.1291/hypres.30.937.
[14]
Prior, J.C. Perimenopause: The complex endocrinology of the menopausal transition. Endocr. Rev. 1998, 19, 397–428, doi:10.1210/er.19.4.397.
[15]
Jesmin, S.; Islam, A.S.; Akter, S.; Islam, M.M.; Sultana, S.N.; Yamaguchi, N.; Okazaki, O.; Moroi, M.; Hiroe, M.; Kimura, S.; et al. Metabolic syndrome among pre- and post-menopausal rural women in Bangladesh: Result from a population-based study. BMC Res. Notes 2013, 6, 157, doi:10.1186/1756-0500-6-157.
[16]
Salve, H.; Mahajan, S.; Misra, P. Prevalence of chronic kidney diseases and its determinants among perimenopausal women in a rural area of North India: A community-based study. Indian J. Nephrol. 2012, 22, 438–443, doi:10.4103/0971-4065.106035.
[17]
Ostlund, R.E., Jr.; Staten, M.; Kohrt, W.M.; Schultz, J.; Malley, M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N. Engl. J. Med. 1990, 322, 229–234, doi:10.1056/NEJM199001253220404.
[18]
Knapp, M.L.; Hadid, O. Investigations into the negative interference by jaundiced plasma in kinetic Jaffe’s methods for plasma creatinine estimation. Ann. Clin. Biochem. 1987, 24, 85–97.
[19]
Gundogan, K.; Bayram, F.; Gedik, V.; Kaya, A.; Karaman, A.; Demir, O.; Sabuncu, T.; Kocer, D.; Coskun, R. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch. Med. Sci. 2013, 9, 243–253.
[20]
Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645.
[21]
International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome Part 1: Worldwide Definition for Use in Clinical Practice. Available online: http://www.idf.org/webdata/docs/IDF_metasyndrome_definition.pdf (accessed on 11 May 2007).
[22]
Levey, A.S.; Coresh, J.; Balk, E.; Kausz, A.T.; Levin, A.; Steffes, M.W.; Hogg, R.J.; Perrone, R.D.; Lau, J.; Eknoyan, G.; et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann. Intern. Med. 2003, 139, 137–147, doi:10.7326/0003-4819-139-2-200307150-00013.
[23]
Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288, 2709–2716, doi:10.1001/jama.288.21.2709.
[24]
Laaksonen, D.E.; Lakka, H.M.; Niskanen, L.K.; Kaplan, G.A.; Salonen, J.T.; Lakka, T.A. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 2002, 156, 1070–1077, doi:10.1093/aje/kwf145.
[25]
Gharipour, M.; Kelishadi, R.; Khosravi, A.; Shirani, S.; Masjedi, M.; Sarrafzadegan, N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: Findings from the Isfahan Healthy Heart Program, 2001–2007. Arch. Med. Sci. 2012, 8, 1009–1017.
[26]
Chen, J.; Muntner, P.; Hamm, L.L.; Jones, D.W.; Batuman, V.; Fonseca, V.; Whelton, P.K.; He, J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern. Med. 2004, 140, 167–174, doi:10.7326/0003-4819-140-3-200402030-00007.
[27]
Gluba, A.; Mikhailidis, D.P.; Lip, G.Y.; Hannam, S.; Rysz, J.; Banach, M. Metabolic syndrome and renal disease. Int. J. Cardiol. 2013, 164, 141–150, doi:10.1016/j.ijcard.2012.01.013.
[28]
Kurella, M.; Lo, J.C.; Chertow, G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 2005, 16, 2134–2140, doi:10.1681/ASN.2005010106.
[29]
Zhang, L.; Zuo, L.; Wang, F.; Wang, M.; Wang, S.; Liu, L.; Wang, H. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin. Proc. 2007, 82, 822–827, doi:10.4065/82.7.822.
